NCT07050511View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

November 22, 2024

Study Completion Date

November 22, 2024

Conditions
SARS CoV-2
Interventions
DRUG

GB-0669

Single IV infusion of GB-0669.

DRUG

Placebo

Single IV infusion of placebo. Sterile 0.9% (w/v) sodium chloride solution.

Trial Locations (1)

02143

Generate Biomedicines, Somerville

Sponsors
All Listed Sponsors
lead

Generate Biomedicines

INDUSTRY